Data from the phase 2 EXTEND trial showed that the addition of metastasis-directed therapy to ADT improved measures of systemic disease control.

In this video, Laura Bukavina, MD, MSc, MPH, and Betty Wang, MD, discuss the intersection of circulating tumor DNA (ctDNA) monitoring with emerging therapies for non–muscle invasive bladder cancer ...

Sonam Saxena highlights a study on factors that may predict failure of robotic ureteroplasty with buccal mucosa graft.

Recent data published in JAMA Oncology show that 1 in 6 men with grade group 1 (GG1) prostate cancer ultimately had intermediate- to high-risk disease when other clinical features were taken into ...

Jansen stresses that testosterone is not a cure-all and often requires adjunct evaluation and management of other conditions such as sleep apnea or thyroid disorders.

An expert summarizes that the emerging concept of broad immune potentiation—exemplified by therapies like Terra-002—seeks to activate multiple immune pathways for a more durable antitumor response in ...

An expert summarizes that the emerging concept of broad immune potentiation—exemplified by therapies like Terra-002—seeks to activate multiple immune pathways for a more durable antitumor response in ...

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

Preclinical data shared during the 4th Annual Targeted Radiopharmaceuticals Summit (TRP) in San Diego, California, showed that the targeted radiotherapy ATNM-400 achieved robust antitumor efficacy in ...

Welcome to Urology Times’ ® monthly FDA update! In July, notable advancements were made in the development of a combination regimen for metastatic prostate cancer, an emerging agent in non–muscle ...